Eupraxia Pharmaceuticals Inc. (FRA:X43)
Germany · Delayed Price · Currency is EUR | Market Cap | 402.70M +69.2% |
| Revenue (ttm) | n/a |
| Net Income | -46.11M |
| EPS | -0.90 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9 |
| Open | 6.80 |
| Previous Close | 6.85 |
| Day's Range | 6.80 - 6.80 |
| 52-Week Range | 4.42 - 8.05 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company’s product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the ... [Read more]
News
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging i...
Eupraxia Pharmaceuticals reaches enrollment target for RESOLVE study
Eupraxia Pharmaceuticals (EPRX) announced that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis, or EoE, has reached its enrollmen...
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging i...
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging i...
Eupraxia announces data from Phase 1b/2a RESOLVE study of EP-104GI
Eupraxia Pharmaceuticals (EPRX) announced updated clinical data from the Phase 1b/2a RESOLVE study highlighting the long duration of response, high remission rates and tolerability of EP-104GI for the...
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ...
Wedbush bullish on Eupraxia Pharmaceuticals, initiates with an Outperform
As previously reported, Wedbush initiated coverage of Eupraxia Pharmaceuticals (EPRX) with an Outperform rating and $17 price target The firm sees eosinophilic esophagitis as the next major investor o...
Eupraxia Pharmaceuticals initiated with an Outperform at Wedbush
Wedbush initiated coverage of Eupraxia Pharmaceuticals (EPRX) with an Outperform rating and $17 price target
Eupraxia Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
EoE is a rapidly growing market with significant unmet need, and the therapy’s once-yearly, physician-administered dosing offers strong compliance and commercial advantages. Detailed interim phase II-B data in December will address efficacy, durability, and safety, supporting expansion into additional indications.
Eupraxia Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted a novel drug delivery platform for EoE, showing rapid and sustained symptom relief, strong histological improvements, and a favorable safety profile. The upcoming phase II-B trial is expected to confirm these benefits, with significant commercial and pipeline expansion potential.
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (Nasdaq: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveragin...
Eupraxia Pharmaceuticals management to meet with Oppenheimer
Meeting to be held on September 9 hosted by Oppenheimer.
Eupraxia Pharmaceuticals Slides: Corporate presentation
Eupraxia Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 20, 2026.
Eupraxia Pharmaceuticals Registration statement: Registration filing
Eupraxia Pharmaceuticals filed a registration statement on August 19, 2026, providing details about a securities offering with the SEC.
Eupraxia Pharmaceuticals reports Q2 net income ($14.5M) vs ($8.7M) last year
“Eupraxia is well funded with the experienced talent to execute on key upcoming milestones, including the Phase 2b Eosinophilic Esophagitis (EoE) trial with interim data expected to be released in…
Eupraxia Pharmaceuticals announces results from RESOLVE study analysis
Eupraxia Pharmaceuticals (EPRX) announced results from a new analysis of the RESOLVE study examining the effect of EP-104GI on symptom severity, including for the first time an analysis of the…
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post trea...
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI
Eupraxia Pharmaceuticals Earnings release: Q2 2026
Eupraxia Pharmaceuticals released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Eupraxia Pharmaceuticals MD&A: Q2 2026
Eupraxia Pharmaceuticals filed a regulatory document on August 11, 2026 disclosing important business information.
Eupraxia Pharmaceuticals Report: Q2 2026
Eupraxia Pharmaceuticals published a report on August 11, 2026 containing material business information for investors and shareholders.
Eupraxia Pharmaceuticals Registration statement: Registration filing
Eupraxia Pharmaceuticals filed a registration statement on August 6, 2026, providing details about a securities offering with the SEC.
Eupraxia Pharmaceuticals files $300M mixed securities shelf
06:12 EDT Eupraxia Pharmaceuticals (EPRX) files $300M mixed securities shelf
Eupraxia Pharmaceuticals Slides: Investor presentation
Eupraxia Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Eupraxia chief scientific and operating officer Amanda Malone steps down
Eupraxia Pharmaceuticals (EPRX) announced Amanda Malone has stepped down from her role as chief scientific and operating officer, effective July 10. Eupraxia is grateful for her years of expertise in…